Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac or the mRNA Vaccine (Comirnaty) in Turkey

Next Previous
X
Search
Trial Profile

A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac or the mRNA Vaccine (Comirnaty) in Turkey

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Sponsors Sinovac Biotech

    • Most Recent Events

    • 09 Aug 2022 Planned primary completion date changed from 15 Jan 2022 to 15 Jan 2023.
    • 09 Aug 2022 Status changed from not yet recruiting to suspended.
    • 15 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top